A personalized anticancer vaccine shows, for the first time, a benefit in patients

A groundbreaking cancer vaccine developed by Moderna, based on messenger RNA, shows promising results in preventing melanoma recurrence. The clinical trial revealed a significant increase in the two-year survival rate without recurrence, from 70% with standard treatment to 82% with the personalized vaccine. This innovative approach tailors the vaccine to target specific tumor mutations, enhancing the immune response. The trial, involving over 1,100 patients, marks a significant advancement in cancer treatment, demonstrating the first proven benefit of a personalized cancer vaccine. Experts highlight the clinical relevance of these findings, indicating a substantial improvement in patient outcomes.